Cystine Deprivation Triggers Programmed Necrosis in VHL-Deficient Renal Cell Carcinomas

Xiaohu Tang1, Jianli Wu1, Chien-Kuang Ding1

  • 1Department of Molecular Genetics and Microbiology, Duke University, Durham, North Carolina. Center for Genomic and Computational Biology Duke University, Durham, North Carolina.

Cancer Research
|February 3, 2016
PubMed

Insights

Depriving clear cell renal cancer cells of cystine causes necrosis in VHL-deficient cells, presenting a therapeutic strategy. This approach targets cancer cell nutrient addiction and may bypass drug resistance mechanisms.

Area of Science:

  • Oncology
  • Cancer Metabolism
  • Molecular Biology

Background:

  • Cancer cells often reprogram metabolism to rely on extracellular nutrients.
  • Identifying specific nutrient dependencies is crucial for developing targeted therapies.
  • Clear cell renal cell carcinoma (ccRCC) exhibits VHL gene alterations impacting cellular metabolism.

Purpose of the Study:

  • To investigate the impact of amino acid deprivation on VHL-deficient and VHL-restored ccRCC cells.
  • To identify specific nutrient dependencies in ccRCC.
  • To explore therapeutic opportunities targeting nutrient addiction in ccRCC.

Main Methods:

  • Performed a nutrigenetic screen on isogenic ccRCC cell lines with and without VHL.
  • Deprived cells of individual amino acids to observe phenotypic changes.
  • Analyzed cell death pathways (apoptosis and necrosis) and signaling pathways (TNFα, RIPK1, Src-p38, MLKL).
  • Assessed the effect of cystine deprivation on ccRCC xenograft growth.

Main Results:

  • Cystine deprivation induced rapid programmed necrosis in VHL-deficient ccRCC cells, but not in VHL-restored cells.
  • Blocking cystine uptake significantly inhibited ccRCC xenograft growth.
  • Metabolic changes were similar regardless of VHL status, indicating non-metabolic factors drive differential cell fates.
  • VHL loss-associated TNFα and RIPK1 activation rendered VHL-deficient cells susceptible to cystine-deprivation-induced necrosis.

Conclusions:

  • Cystine deprivation represents a promising therapeutic strategy for VHL-deficient ccRCC.
  • This approach may overcome apoptosis-evasion mechanisms common in drug-resistant cancers.
  • Targeting cystine metabolism offers a potential avenue for ccRCC treatment, irrespective of VHL status.